2型糖尿病患者中GLP-1受体激动剂对比DPP-4抑制剂或SGLT-2抑制剂的心衰住院风险
该研究模拟两项目标试验,基于瑞典斯德哥尔摩人群数据,纳入新起始GLP-1RA对比DPP-4i或SGLT-2i的2型糖尿病成人患者。主要结局为心衰住院。结果显示,GLP-1RA相比DPP-4i的3年心衰住院绝对风险更低,相比SGLT-2i风险相似。
要点
- 起始GLP-1RA较DPP-4i的3年心衰住院绝对风险更低。
- 起始GLP-1RA与SGLT-2i的心衰住院风险相似。
- 基线心衰预测风险越高的患者,绝对风险差异越大。
核心结论
- 在常规诊疗中,2型糖尿病患者起始GLP-1RA与较低的心衰住院风险相关(对比DPP-4i),与SGLT-2i风险相似。
研究设计与样本
- 基于瑞典斯德哥尔摩2010至2021年人群健康数据模拟两项目标试验。
- 采用Cox回归估计意向治疗风险比,以逆概率治疗加权平衡72个混杂因素。
- 主要不良心血管事件作为阳性对照结局。
主要发现
- GLP-1RA组3年心衰住院绝对风险为3.4%,DPP-4i组为4.3%。
- GLP-1RA对比DPP-4i的心衰住院加权风险比为0.77(95%CI,0.66-0.91)。
- GLP-1RA组3年心衰住院绝对风险为3.6%,SGLT-2i组为3.3%。
- GLP-1RA对比SGLT-2i的心衰住院加权风险比为1.02(95%CI,0.85-1.18)。
- 基线心衰预测风险较高的患者中绝对风险差异最大。
关键数值与推荐
- GLP-1RA对比DPP-4i的心衰住院加权风险比0.77(95%CI,0.66-0.91)。
- GLP-1RA对比SGLT-2i的心衰住院加权风险比1.02(95%CI,0.85-1.18)。
- GLP-1RA对比DPP-4i的主要不良心血管事件加权风险比0.85(95%CI,0.74-0.99)。
临床怎么用
- 对于2型糖尿病患者,在考虑心衰住院风险时,GLP-1RA可优先于DPP-4i。
- GLP-1RA与SGLT-2i在降低心衰住院风险方面表现相似,可结合其他临床因素选择。
- 基线心衰风险较高的患者从GLP-1RA对比DPP-4i的选择中可能获得更大的绝对获益。
局限性
- 研究基于常规诊疗数据,可能存在残余混杂。
- 目标试验模拟方法受限于观察性数据质量和变量记录完整性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Novel treatments are needed for the primary and secondary prevention of heart failure in patients with type 2 diabetes, including individuals with and those without a history of heart failure. Conflicting trial evidence exists on whether glucagon-like peptide-1 receptor agonists (GLP-1RAs) reduce the risk of hospitalization for heart failure (HHF) in this broad population and whether this is a class effect or varies by specific agent. Furthermore, their comparative effectiveness against sodium-glucose cotransporter-2 inhibitors (SGLT-2is) is unknown. METHODS: We emulated 2 target trials using population-based health care data from Stockholm, Sweden (2010-2021). Target trial 1 included adult patients with type 2 diabetes who newly initiated GLP-1RA versus dipeptidyl peptidase-4 inhibitors (DPP-4is), and target trial 2 compared GLP-1RA with SGLT-2i. The primary outcome was HHF. Cox regression was used to estimate intention-to-treat hazard ratios, with inverse probability of treatment weighting used to balance 72 confounders. Major adverse cardiovascular events were used as the positive control outcome. Analyses were conducted for the GLP-1RA class overall and for individual agents, including liraglutide and semaglutide. RESULTS: Target trial 1 included 32 979 patients (42% GLP-1RA and 58% DPP-4i) with a mean age of 64 years and 40% female; and target trial 2 included 30 104 patients (49% GLP-1RA and 51% SGLT-2i) with a mean age of 63 years and 38% female. Starting a GLP-1RA was associated with a lower 3-year absolute risk of HHF than starting a DPP-4i (3.4% versus 4.3%), corresponding to a weighted hazard ratio of 0.77 (95% CI, 0.66-0.91). Absolute 3-year risks for GLP-1RA compared with SGLT-2i on HHF were 3.6% and 3.3% with a weighted hazard ratio of 1.02 (95% CI, 0.85-1.18). The absolute risk difference was largest for patients with higher predicted risk of heart failure at baseline. Results were consistent for single agents, in per-protocol analyses, and in the majority of subgroups. In positive control outcome analyses, GLP-1RA use was associated with a lower rate of major adverse cardiovascular events than DPP-4i use (weighted hazard ratio, 0.85 [95% CI, 0.74-0.99]), consistent with trial findings. CONCLUSIONS: GLP-1RA use is associated with a lower risk of HHF compared with DPP-4i and similar risks compared with SGLT-2i in routine clinical care for patients with type 2 diabetes.
引用
- Xu, Huang, Zhang, et al. Risk of Heart Failure Hospitalization for GLP-1 Receptor Agonists Versus DPP-4 Inhibitors or SGLT-2 Inhibitors in Patients With Type 2 Diabetes: A Target Trial Emulation. Circulation. 2026. PMID: 41732861. doi:10.1161/CIRCULATIONAHA.125.075157
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。